This is my eighth Ligand (NASDAQ: LGND ) article, following my most recent 07/2024's "Ligand Pharmaceuticals: Solid Performer Performing Solidly" (" Solid "). In Solid, I rated Ligand as a "Buy". In the interim, it has risen a modest ~9.6%. InWriting under the pseudonym "out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned. In my Seeking Alpha articles I share my experience from decades of investing ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________________ FORM 10-Q ________________________________________________________________________________________ ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Title of each class: Trading symbol: Name of each exchange on which registered: Common Stock, par value $0.001 per share LGND The Nasdaq Global Market __________ ...

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Melanie Herman - Senior Director of Financial Planning and Analysis Todd Davis - Chief Executive Officer Karen Reeves - Senior Vice President of Investments and Head of Clinical Strategy Tavo Espinoza - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Douglas Miehm - RBC Capital Markets Joseph Pantginis - Wainwright Trevor Allred - Oppenheimer Joh ...

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously$140 million - $157 million) and core adjusted earnings per diluted share increased to $5.50 - $5.70 (previously $5.00 - $5.50) 1 Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., Nov ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________________ FORM 10-Q ________________________________________________________________________________________ ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Title of each class: Trading symbol: Name of each exchange on which registered: Common Stock, par value $0.001 per share LGND The Nasdaq Global Market __________ ...

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Todd Davis - CEO Tavo Espinoza - CFO Paul Hadden - Senior Vice President of Investments and Business Development Karen Reeves - Senior Vice President of Investments and Head of Clinical Strategy Conference Call Participants Matt Hewitt - Craig-Hallum Douglas Miehm - RBC Capital Markets Lawrence Solow - CJS Operator Thank you for standing by. My name is Pam and I will be your conf ...

| --- | --- | --- | |-------------------|---------------------------------------------|-------| | | | | | LIGAND | Biopharma's Technology and Capital Partner | | | Financial Results | Second Quarter 2024 | | | | | | Safe Harbor Statement and Disclaimers • This presentation contains forward-looking statements by Ligand and its partners that involve risks and uncertainties and reflect Ligand's and its partners' judgment as of the date of this presentation. Words such as "plans," "believes," "expects," "antici ...

Ligand Reports Second Quarter 2024 Financial Results Conference call at 4:30 p.m. Eastern Time today JUPITER, Fla., August 06, 2024 – Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to me ...

Therefore, the Zacks rating upgrade for Ligand basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price. Empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively ha ...

A month has gone by since the last earnings report for Ligand Pharmaceuticals (LGND) . Shares have added about 4% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Ligand due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Q1 Earnings Beat, Sales Miss Estimates Ligand re ...